Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drug Layering in Heart Failure: Phenotype-Guided Initiation.

JACC. Heart failure - 1 Nov 2021

Rosano Giuseppe M C, Allen Larry A, Abdin Amr, Lindenfeld Joann, O'Meara Eileen, Lam Carolyn S P, Lancellotti Patrizio, Savarese Gianluigi, Gottlieb Stephen S, Teerlink John, Wintrich Jan, Böhm Michael

Abstract excerpt

Medications with proven benefit in patients with heart failure with reduced ejection fraction are recommended, according to prospective large clinical trials, in the stable patient after careful up-titration in a strict sequential order. Although the relevance of careful clinical up-titration is unproven, there is evidence that after recompensation and shortly after hospital discharge, the rate of cardiovascular...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Heart Failure
Share to Pharmaceutical Preparations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phenotype

Share to Stroke Volume

Source

Identifiers

PMID: 34627725
DOI: 10.1016/j.jchf.2021.06.011

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drug Layering in Heart Failure: Phenotype-Guided Initiation.PMID 34627725Read ↗

Canadian Cardiovascular Society-Canadian Heart Failure Society Focused Clinical Practice Update of Patients With Differing Heart Failure Phenotypes.Semantic proximity Read ↗

Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension.Semantic proximity Read ↗

The emerging role of pharmacogenomics in the treatment of patients with heart failure.Semantic proximity Read ↗

Phenotype-guided approach for device-based therapies in heart failure.Semantic proximity Read ↗

Heterogeneous Treatment Effects in HFpEF: Distinguishing Drug-Specific Response from Prognostic Phenotypes Across Randomized TrialsSemantic proximity Read ↗

Clinical phenotypes according to diuretic combination in acute heart failure.Semantic proximity Read ↗

[Medication treatment in pulmonary arterial hypertension with comorbidities - Which phenotypes and points to consider].Semantic proximity Read ↗

Dressing heart-failure patients on Savile Row--tailored treatment?Semantic proximity Read ↗

Medications for specific phenotypes of heart failure with preserved ejection fraction classified by a machine learning-based clustering model.Semantic proximity Read ↗

SGLT2i, ARNi and Diuretic Use in Patients with Heart Failure Among the Preserved and Reduced Ejection Fraction: A Retrospective Observational StudySemantic proximity Read ↗

Strategies for pharmacologic modulation of the heart failure phenotype.Semantic proximity Read ↗

New Management Strategies in Heart Failure.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.